SCHEMBL7030926

SCHEMBL7030926

CCCCn1cnc2c1c(=O)n(CCCCC(C)(C)O)c(=O)n2C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 7/20 0.62
▸ LMNA P02545 3/20 0.62
▸ CYP1A2 P05177 2/20 0.62
▸ NFKB1 P19838 2/20 0.62
▸ ACHE P22303 2/20 0.62
▸ PMP22 Q01453 2/20 0.62
▸ ESR1 P03372 1/20 0.62
▸ MAPT P10636 1/20 0.62
▸ BLM P54132 1/20 0.62
▸ ADORA2A P29274 4/20 0.58
▸ PDE4B Q07343 6/20 0.55
▸ PDE4C Q08493 6/20 0.55
▸ PDE4D Q08499 6/20 0.55
▸ ADORA2B P29275 6/20 0.55
▸ RXFP1 Q9HBX9 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ TNF P01375 2/20 0.49
▸ USP2 O75604 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10346307 0.95 LMNA (0.61) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL10346583 0.94 PDE4A (0.64) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL5427270 0.94 PDE4A (0.70) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL7358934 0.93 PDE4A (0.69) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL10346588 0.91 PDE4A (0.68) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL19601304 0.91 PDE4A (0.58) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL9057453 0.90 PDE4A (0.60) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL7033527 0.89 PDE4A (0.58) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL10346304 0.88 LMNA (0.56) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL11059115 0.88 PDE4A (0.73) PDE4ALMNACYP1A2NFKB1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6432968-B1 IMMUNOSUPPRESSANTS FOR PATIENTS WITH CANCER, AUTOIMMUNE DISEASES, AND VIRAL INFECTIONS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-08-13 — — US claimed
EP-0797448-A2 COMBINATION PREPARATION, CONTAINING CYCLOSPORIN A OR FK506 OR RAPAMYCIN AND A XANTHINE DERIVATIVE HOECHST AKTIENGESELLSCHAFT (DE) 1997-10-01 — — EP claimed
WO-1996005854-A2 COMBINATION PREPARATION, CONTAINING CYCLOSPORIN A OR FK506 OR RAPAMYCIN AND A XANTHINE DERIVATIVE HOECHST AKTIENGESELLSCHAFT (DE) 1996-02-29 — — WO claimed
EP-0797448-B1 COMBINATION PREPARATION, CONTAINING CYCLOSPORIN A OR FK506 OR RAPAMYCIN AND A XANTHINE DERIVATIVE HOECHST AG (DE) 2003-02-26 — — EP disclosed
US-6432968-B1 IMMUNOSUPPRESSANTS FOR PATIENTS WITH CANCER, AUTOIMMUNE DISEASES, AND VIRAL INFECTIONS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-08-13 — — US disclosed
US-6046328-A Combination preparation, containing cyclosporin A or FK506 or rapamycin and a xanthine derivative AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-04-04 — — US disclosed
EP-0797448-A2 COMBINATION PREPARATION, CONTAINING CYCLOSPORIN A OR FK506 OR RAPAMYCIN AND A XANTHINE DERIVATIVE HOECHST AKTIENGESELLSCHAFT (DE) 1997-10-01 — — EP disclosed
WO-1996005854-A2 COMBINATION PREPARATION, CONTAINING CYCLOSPORIN A OR FK506 OR RAPAMYCIN AND A XANTHINE DERIVATIVE HOECHST AKTIENGESELLSCHAFT (DE) 1996-02-29 — — WO disclosed
Send feedback